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Objective: to assess the predictivity of clinical variables in patients with chronic critical leg ischaemia (CLI).
Design: observational prospective cohort study.
Methods: the i.c.a.i. (ischemia critica degli arti inferiori) trial database was used to assess the impact of patients’
history, cardiovascular risk, manifestations of the disease and specific invasive and pharmacological interventions on
mortality, amputation rate and persistence of CLI.
Results: of 1560 patients, 298 died within one year; at six months 187 were amputees and 746 still suffered from CLI.
Prior major vascular events doubled the risk of dying within one year. Previous revascularisation was associated with a
lower mortality, but also with a higher probability of amputation. Among cardiovascular risk factors, only diabetes affected
prognosis, in terms of increased mortality and lower probability of recovery from CLI. Patients with tissue loss had a
higher amputation rate and less probability of recovery. Ankle pressure was predictive of mortality and amputation only
when unmeasurable. Patients requiring revascularisation had better chances of recovering from CLI, but not of longer-
term survival or limb salvage compared to those in whom surgery was deemed unnecessary. Antiplatelet drugs caused
resolution of CLI and decreased the amputation rate by about 1/3, while the advantage of the test treatment (alprostadil-
a-cyclodextrine) was confined to CLI resolution only.
Conclusions: this study documents the high mortality and heterogeneity of patients with CLI. It provides stratification
criteria for reliably estimating the achievable benefit in routine practice and for clinical trials.
Key Words: Critical leg ischaemia; Prognostic variables; Cohort study.
Introduction relation to previous and concurrent interventions and
treatments. As PAOD and CLI have been suggested as
the local expression of more generalised pathologicalThe clinical, epidemiological and public health import-
processes, closer attention to these aspects might wellance of peripheral occlusive artery disease (PAOD) has
provide useful information for focusing research andbeen increasingly recognised over the last decade.1 The
care strategies.definition of its specific features and severity of the
We analysed the population of CLI patients enrolledprognosis in the various stages has been the task of a
in the i.c.a.i. (ischemia critica degli arti inferiori) trial,12,13consensus group, with the aim of providing guidelines
which found that prolonged treatment with i.v. pro-for testing preventive and therapeutic interventions.2,3
stanoids achieved only a brief benefit on CLI. This largeThe advanced stages of PAOD, i.e. critical leg ischaemia
clinical cohort was prospectively followed for up to one(CLI) have a particularly poor prognosis with respect
year. The larger population and the controlled settingto both mortality and morbidity.4–7 Current definitions
of this study provide an extension of the findings re-of CLI2,8–10 are mainly based on presenting signs and
ported in the epidemiological survey previously con-symptoms and ankle systolic pressure (ASP), but have
ducted by the i.c.a.i. group,5,7 which only focused onvery limited predictive value.11 Little is known about
mortality.the many more acute and chronic clinical and epi-
demiological variables in terms of co-morbidity, and in
Methods
* The members of the i.c.a.i. (i.e. chronic critical leg ischaemia (CLI)) The clinical data base of the i.c.a.i. trial and the mortality
Group are listed in the Acknowledgements.
data obtained through census offices were used to as-† Please address all correspondence to: V. Bertele`, “Mario Negri”
Institute, via Eritrea 62, 20157 Milan, Italy. sess how different anamnestic and clinical variables of
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aCLIpopulationaffected itsclinicaloutcome.The i.c.a.i. clinical-record forms and in agreement with the Inter-
national External Safety and Efficacy Monitoring Com-was a multicentre, controlled, centrally randomised,
open-label trial of the efficacy and safety of prostanoids mittee, all information on the six-month outcome of the
226 patients recruited by those centres was considered(in this case the stable PGE1 alprostadil-a-cyclodextrine)
in CLI. The trial method and results have been reported unreliable and excluded from the analysis.13 In addition,
six patients from the experimental group and sevenelsewhere.12,13 “Good Clinical Practice” criteria were ad-
optedfor theapprovalof thestudyprotocolbypertinent from the control group were lost to follow-up at six
months. The outcome analysis therefore concerns: (a)regional and local human experimentation committees,
for informed-consent procedures, monitoring and aud- the entire cohort (1560 patients) for outcome data at
discharge and for mortality data at six and twelveiting of the activities of the participating centres, and
for documentation, revision and analysis of outcome. months (verified through census offices but 9 untraced
cases); (b) the cohort of 1334 patients with reliable re-Fifty-six National Health Service vascular surgery
and angiology departments recruited 1560 patients suf- porting of major amputations and of persistent CLI dur-
ing the six-month follow-up for long-term “peripheralfering from leg ischaemia considered as chronic and
critical according to clinical inclusion criteria (i.e. per- outcome”.
sistently recurring rest pain for at least two weeks and/
or foot ulcers or gangrene). The clinical diagnosis was
confirmed by Doppler sonography and/or angio-
Potential prognostic predictorsgraphy. ASP was used to allow appropriate strat-
ification and analysis, although it was not among the
In order to assess their predictive value, mortality, am-inclusion criteria, since there is no general agreement
putation rate and CLI resolution were analysed withon its contribution to the definition of CLI11,14,15 and one
respect to the main demographic and clinical variables:of the aims of this study was to assess its prognostic
namely, age; sex; hypertension (defined as systolicvalue.
blood pressure [160 mmHg and/or diastolic bloodOf the 2582 CLI patients considered for the i.c.a.i.
pressure [95 mmHg, or presence of antihypertensivestudy,1022with(a)agebelow18; (b) immediateneedfor
treatment); diabetes (fasting blood glucosemajor amputation; (c) contraindications to prostanoids;
[7.8 mmol/l (140 mg/dl) or ongoing treatment with(d) severe diseases, either not adequately controlled or
insulin or oral hypoglycemic agents); hyper-with a poor six-month prognosis for reasons unrelated
cholesterolaemia (total serum cholesterol [6.4 mmol/lto CLI, were excluded from the trial.
[250 mg/dl] or ongoing cholesterol-lowering treat-
ment); obesity (body mass index – [(body weight in
kg)/(height in m)2] – [30); history of myocardial
infarction or stroke, claudication, major or minor
amputation, revascularisation procedures (bypass,Outcome measures
thromboendoarterectomy (TEA), percutaneous trans-
luminal angioplasty – PTA); diagnostic variables suchThe outcome measures considered were: death at 6 and
12 months, major amputation and CLI at 6 months. Am- as Fontaine’s stage, ASP, ankle–brachial pressure index
(ABPI), level and number of vascular occlusions; in-putations at or above the ankle were considered major.
CLI had to be documented with the same diagnostic hospital revascularisation procedures (as well as their
suitability and practicability), main pharmacologicalcriteria used at recruitment. To achieve a more homo-
geneous and objective evaluation, ulcers were con- (vasoactive, anticoagulant, antiplatelet) and other in-
terventions, invasive (sympathectomy, epidural spinalsidered healed only when re-epithelialisation was
complete; a reduction in number or diameter was not stimulation (ESES) or minor amputation) or non-
invasive measures (peridural anaesthesia, lumbarconsidered sufficient. Since CLI was the condition
under study, present by definition in all patients at re- chemical sympathectomy, hyperbaric oxygen therapy).
The level of vascular occlusions was hierarchicallycruitment, the opposite positive event (e.g. CLI res-
olution) was considered as the outcome measure in the defined, and the opposite order was assumed as rel-
evant in terms of death and of peripheral outcomes;analysis.
A cross-check of follow-up data through census of- i.e. for death, an abdominal occlusion defined the
level as abdominal regardless of the presence of morefices or the patients themselves or their relatives re-
vealed incorrect reporting of outcome events for 18 peripheral occlusions, while for amputation and per-
sistent CLI a distal occlusion established the levelpatients followed by five centres. In the absence of
source documents against which to check individual regardless of the presence of more proximal occlusions.
Eur J Vasc Endovasc Surg Vol 18, November 1999
Outcome Predictors in Critical Leg Ischaemia 403
Table 1. Characteristics of the study population and of the index Table 2. Non-experimental in-hospital treatments
clinical picture
Total
n=1560Total
n=1560
Pharmacological treatments: no. %
Age: mean years–s.d. 70.8–10.1
Analgesic
Non-narcotic (NSAID and others) 1134 (72.7)no. %
Males 1132 (72.6) Narcotic (buprenorphine and others) 133 (8.5)
Previous cardiovascular morbidity: Vasoactive (pentoxifylline, buflomedil 892 (57.2)
myocardial infarction 222 (14.2) etc.)
stroke 179 (11.5)
Antithromboticclaudicatio intermittens 1329 (85.2)
Antiplatelet 495 (31.7)
Previous surgery: Heparin 859 (55.1)
reconstructive surgery 256 (16.4) Oral anticoagulant 86 (5.5)
PTA 53 (3.4) Thrombolytic 18 (1.2)
amputation Defibrotide 97 (6.2)
• major 80 (5.1)
Revascularisation procedures: 570 (36.5)• minor 97 (6.2)
Bypass 468 (30.0)
Risk factors: TEA 72 (4.6)
arterial hypertension 749 (48.0) PTA 64 (4.1)
diabetes mellitus 615 (39.4) • with thrombolysis 5 (0.3)
hypercholesterolaemia 250 (16.0) Thrombectomy 40 (2.6)
obesity 96 (6.2)
Others:smoking
Sympathectomy 142 (9.1)• past 688 (44.1)
Epidural stimulation 56 (3.6)• current 414 (26.5)
Minor amputation 118 (7.6)
CLI diagnostic variable: Peridural analgesia 311 (19.9)
Pain only 485 (31.1) Lumbar sympathetic blockade 30 (1.9)
Pain and/or ulcer 1075 (68.9) Oxygen therapy 14 (0.9)
Analgesic consumption 949 (60.8)
Ankle systolic pressure
• not measured 299 (19.2) particularly heparin and antiplatelet agents (Table 2).• >50 mmHg 538 (34.5)
More than one-third of the patients underwent re-• Z50 mmHg 723 (46.3)
vascularisation procedures, mostly vascular re-Instrumental diagnosis
• Doppler 1250 (80.1) constructive interventions (Table 2). About one-quarter
• Angiography 1124 (72.1) (n=367) were considered inoperable on account of the• Either or both 1526 (97.8)
local disease (12.2%), their general condition (6.0%)
or both (5.3%). Revascularisation was deemed not
immediately necessary in 28.3%. Other reasons forFirstly, the univariate Mantel–Haenszel estimate of non-intervention (e.g. postponement, patients denyingrelative risk was assessed; the variables which ap- consent) were less frequent. Alternative procedures,peared to be associated with the outcome measure such as epidural analgesia, were employed in 41.2%with a p value <0.10 were then entered in a multivariate of cases, mostly in patients not undergoing re-analysis using the Cox regression model. The resulting vascularisation (Table 2).exploratory model is presented in terms of relative The age-adjusted independent predictors of deathrisk (RR) and 95% confidence interval (CI). Student’s and peripheral outcome assessed by the Cox regression
t-test and the Mantel–Haenszel test were used re- model are reported in the figures. Since the factorsspectively to assess the significance of the differences affecting mortality at six months and one year werefor means and proportions. The significance of the the same and their prognostic values in terms oflinear trends in risk was assessed by the Mantel v2- relative risks and confidence intervals were almostfor-trend test. identical, only results at one year are shown (Fig. 1).
The overall mortality of the study cohort was 13.4%
at six months (data not shown) and 19.1% at 12 months
(Fig. 1); by the end of the clinical observation periodResults
12% had been amputated (Fig. 2) and 47.8% had
persistent CLI (Fig. 3). Age affected all clinical out-Table 1 describes the baseline characteristics of the
study population. Besides analgesics (mainly non-nar- comes: each year of age increased the risk of dying
within 6 or 12 months by about 5%, the risk of beingcotic), in-hospital pharmacological treatment was gen-
erally based on vasoactive and antithrombotic drugs, amputated by about 2% and the probability of not
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3.5
141/771 0.68–1.07
0
prognosis worse
3
Yes 0.85
1 1.5 2 2.5
prognosis better
0.5
157/789No 1.0
Alprostadil:
73/480 0.59–1.01Yes 0.78
225/1080No 1.0
Antiplatelet drugs:
102/367 1.41–2.64Impracticable 1.93
68/442Unnecessary 1.0
Revascularisation:
42/174 1.02–2.26Not performed for other reasons 1.52
86/577 0.78–1.51Performed 1.08
INTERVENTIONS
157/854 0.57–0.94Infra-inguinal 0.74
123/603Abdominal 1.0
Level of obstruction:
10/79 0.27–1.00Distal 0.52
8/24 0.76–3.39Not known 1.61
34/235 0.60–1.3431–50 mmHg 0.89
89/538>50 mmHg 1.0
ASP:
18/86 0.70–1.951–30 mmHg 1.17
105/402 1.14–2.030 mmHg 1.52
CLINICAL PICTURE
52/299 0.81–1.63Not measured 1.15
134/615 1.05–1.68Yes 1.33
164/945No 1.0
Diabetes:
RISK FACTOR
16/80 0.53–1.50Major amputation 0.90
215/1059No previous intervention 1.0
Intervention:
21/94 0.68–1.70Minor amputation 1.08
28/234 0.42–0.95Revascularisation 0.63
18/93 0.47–1.26Other 0.77
107/370 1.45–2.34Yes 1.84
191/1190No 1.0
MI/stroke:
VASCULAR HISTORY 
OVERALL 298/1560
Dead/total 95% CIRR
Fig. 1. Age-adjusted independent predictors of death at 12 months (Cox regression). The results are presented in terms of relative risk
(RR, E) with its 95% confidence interval (CI, —).
recovering from CLI by about 1% (data not shown). Sex months (Fig. 1), while previous major amputations
did not predict a worse outcome in terms of mortalityhad no influence on the outcome measures considered.
A history of MI or stroke appeared to be a strong or amputation or CLI resolution (Figs 1–3). Previous
minor amputation per se apparently implied a greaterpredictor of mortality at six (data not shown) and 12
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3.5
87/771 0.67–1.20
0
prognosis worse
3
Yes 0.89
1 1.5 2 2.5
prognosis better
0.5
100/789No 1.0
Alprostadil:
50/480 0.49–0.96Yes 0.68
137/1080No 1.0
Antiplatelet drugs:
78/367 1.64–3.81Impracticable 2.50
33/442Unnecessary 1.0
Revascularisation:
19/174 0.90–2.81Not performed for other reasons 1.59
57/577 0.75–1.90Performed 1.20
INTERVENTIONS
36/476 0.45–0.97Infra-inguinal 0.66
147/1004
Abdominal
1.0
Level of obstruction:
3/56 0.20–2.08
Distal
0.65
1/24 0.06–3.22Not known 0.44
24/235 0.75–2.0731–50 mmHg 1.24
42/538>50 mmHg 1.0
ASP:
13/86 0.95–3.341–30 mmHg 1.78
81/402 1.59–3.420 mmHg 2.33
CLINICAL PICTURE
27/299 0.80–2.17Not measured 1.32
81/615 0.85–1.57Yes 1.15
106/945No 1.0
Diabetes:
RISK FACTOR
11/80 0.60–2.14Major amputation 1.13
105/1059No previous intervention 1.0
Intervention:
19/94 1.10–3.00Minor amputation 1.82
38/234 1.19–2.59Revascularisation 1.76
14/93 0.62–1.92Other 1.09
69/344 1.69–3.23Yes 2.33
118/1216No 1.0
Other interventions:
VASCULAR HISTORY 
OVERALL 187/1560
Amputated/total 95% CIRR
149/1075 1.13–2.38Yes 1.64
38/485No 1.0
Ulceration:
174/1433 0.73–2.30Yes 1.29
13/127No 1.0
Pain:
Fig. 2. Age-adjusted independent predictors of amputation at six months. Data are evaluated and presented as in Fig. 1.
probability of subsequent major amputation (Fig. 2). needing amputation (Fig. 2). Diabetes increased the
risk of death at six (data not shown) and 12 monthsPrevious revascularisation procedures were associated
with a lower risk of dying both at six (data not shown) (Fig. 1), but did not significantly affect the risk of
amputation (Fig. 2). In addition, diabetics were lessand 12 months (Fig. 1) but with an increased risk of
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3.5
433/771 1.13–1.50
0
prognosis worse
3
Yes 1.30
1 1.5 2 2.5
prognosis better
0.5
381/789No 1.0
Alprostadil:
282/480 1.11–1.49Yes 1.28
532/1080No 1.0
Antiplatelet drugs:
109/367 0.39–0.61Impracticable 0.49
253/442Unnecessary 1.0
Revascularisation:
73/174 0.54–0.92Not performed for other reasons 0.70
379/577 1.04–1.50Performed 1.25
INTERVENTIONS
258/476 0.80–1.09Infra-inguinal 0.93
508/1004
Abdominal
1.0
Level of obstruction:
40/56 1.12–2.21
Distal
1.58
8/24 0.21–0.88Not known 0.43
143/235 1.00–1.5131–50 mmHg 1.23
285/538>50 mmHg 1.0
ASP:
43/86 0.80–1.531–30 mmHg 1.10
171/402 0.68–1.010 mmHg 0.83
CLINICAL PICTURE
172/299 0.77–1.14Not measured 0.93
271/615 0.63–0.86Yes 0.74
543/945No 1.0
Diabetes:
RISK FACTOR
35/80 0.61–1.23Major amputation 0.87
567/1059No previous intervention 1.0
Intervention:
35/94 0.52–1.04Minor amputation 0.73
136/234 0.73–1.07Revascularisation 0.88
41/93 0.68–1.29Other 0.93
170/344 0.76–1.08yes 0.91
644/1216No 1.0
Other interventions:
VASCULAR HISTORY 
OVERALL 814/1560
Recovered/total 95% CIRR
440/1075 0.22–0.30Yes 0.26
374/485No 1.0
Ulceration:
784/1433 0.55–0.94Yes 0.72
66/127No 1.0
Pain:
Fig. 3. Age-adjusted independent predictors of CLI resolution at six months. Data are evaluated and presented as in Fig. 1.
likely than non-diabetic patients to recover from CLI Prognostic relevance of the clinical picture at recruitment
(Fig. 3). Hypertension, smoking and hypercho-
lesterolaemia did not appear to influence the outcome Univariate analysis indicated the severity of the peri-
pheral manifestations of the disease as associated withmeasures.
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higher mortality. In patients with ulcers or gangrene Other interventions, such as sympathectomy, epi-
dural electrostimulation, or minor amputation, did not(Fontaine’s stage IV) mortality was higher than in
patients with persistently recurring rest pain only affect outcome. On the whole, peridural anaesthesia,
lumbar chemical sympathectomy or hyperbaric-oxy-(stage IIIb). The difference in mortality between the
two groups was statistically significant at 12 months: gen therapy were associated with a higher probability
of amputation (Fig. 2), but not of dying or of persistent221 of the 1075 patients at stage IV died (20.6%)
compared to 77/485 at stage IIIb (16.8%, RR 1.20, CLI. Among the most common pharmacological treat-
ments, neither vasoactive nor anticoagulant agents95%CI 1.02–1.64, p=0.03). Controlling for possible con-
founding variables, the multivariate analysis did not affected mortality, amputation rate or CLI. Antiplatelet
agents, though not providing significant protectionconfirm this association, meaning that the presence of
ulcer or gangrene per se did not actually imply higher against mortality (Fig. 1), reduced amputation and
promoted recovery (Figs 2 and 3). A single course ofmortality. However, the presence of trophic lesions
increased the risk of amputation (Fig. 2). Ulcers and the stable PGE1 alprostadil-a-cyclodextrine, enhanced
CLI recovery (Fig. 3), though it did not affect mortalitypain were independently negatively associated with
CLI resolution, meaning that pain itself – regardless or amputation rates.
of the presence of ulcers – has a predictive value,
though less marked (Fig. 3). Infrainguinal lesions were
associated with a lower mortality rate than more prox-
Discussionimal obstructions (Fig. 1). Distal obstructions were
predictive of a higher amputation and lower CLI
This large prospective cohort study confirms theresolution (Figs 2 and 3). Mortality and persistence of
poor prognosis of CLI. The mortality rate at 12CLI were significantly higher in a small group of 24
months (overall 19.1%) indicates that the prognosispatients for whom the levels of vascular occlusion
is similar to that of myocardial infarction and stroke,were not reported (data not shown). Data from clinical
once the age factor is taken into account.16,17 It isrecord forms could not explain this finding. As ex-
therefore worth underlining the scant attention stillpected, some association was observed between peri-
given to CLI compared with other cardiovascularpheral blood pressure and survival and peripheral
events, even though they share various underlyingoutcome: the lower the ASP the higher the risk of
risk factors and possibly also therapeutic measuresdying (Fig. 1, v2 trend=12.536, p=0.0004), becoming
(as suggested by the role of antiplatelet drugs). Thean amputee (Fig. 2, v2 trend=32.985, p<0.0001) or
specific new information provided by this studymaintaining symptoms and signs of CLI (Fig. 3, v2
includes the prognostic role of peripheral events andtrend=11.757, p=0.0006). However, only undetectable
clinical characteristics with respect to mortality, theankle pressure was formally predictive of mortality
utility of clinical history and baseline variables forand amputation (Figs 1 and 2).
predicting peripheral outcomes. This study shows
the predictive value of variables possibly overlooked
in the previous survey by the i.c.a.i. group.7 ThisPrognostic relevance of in-hospital treatments
involved patients with more severe manifestations of
the disease, for instance those requiring undeferrableThe suitability and practicability of revascularisation
procedures profoundly affect the prognosis of patients amputation, who were excluded from the subsequent
trial and the present analysis. The more advancedwith CLI. Compared with patients for whom vascular
surgery was deemed unnecessary, the risk of dying average stage of the disease in that population may
have hidden the contribution of factors that arewithin six or 12 months was double among patients
considered unsuitable for intervention. Mortality was nevertheless important in its overall natural history.
Prior major cardiovascular events can obviouslyalso higher among patients not undergoing re-
vascularisation for other reasons (Fig. 1). In both these reduce life expectancy7,18 but do not increase the
probability of amputation among survivors; previoussubgroups the probability of recovering from CLI was
lower (Fig. 3). The likelihood of amputation, however, revascularisation improves survival, but these
patients are more-likely candidates for amputation.was greater only among patients unsuitable for re-
vascularisation (Fig. 2). Revascularisation was as- The fact that coronary or cerebrovascular events
have no negative effect on the peripheral outcome,sociated with a risk of death and amputation similar
to that for patients for whom surgery was deemed while peripheral intervention provides some pro-
tection against mortality but not amputation, seemsunnecessary (Figs 1 and 2). However, it was associated
with a better chance of CLI resolution (Fig. 3). to contrast with the view of atherothrombosis as a
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systemic disease. Although revascularisation pro- Prophylaxis with antiplatelet agents, known to
prevent mortality and coronary and cerebrovascularcedures might favour survival by preventing systemic
morbidity in larger studies22,23 or meta-analyses,24diffusion of infections, activated platelets or blood-
was associated here with better peripheral outcomeclotting factors, inflammatory mediators or toxic
in terms of leg salvage and recovery from CLI. Thismetabolites, it is not clear why they do not offer a
supports the concept of peripheral protection bylocal benefit in terms of leg salvage. In line with its
antiplatelet agents,24 a question often disregarded inrole as a major cardiovascular risk factor, diabetes
trials addressing major cardiovascular events asis also associated with a higher mortality risk, in
outcome measures. This multivariate analysisagreement with some observations6,19 but in contrast
strengthens the findings of the i.c.a.i. trial,13 thatwith others.7,11,20,21 Though reducing the chances of
the short-term protection offered by alprostadil isCLI recovery, diabetes has no impact on amputation.
independent of several confounding variables andAlso surprising is the apparent lack of influence of
actually applies to the overall six-month study period.cardiovascular risk factors – particularly smoking –
Although this analysis concerns a population selectedon mortality and peripheral outcome. However, this
for a trial, the few exclusion criteria and their naturedoes confirm the i.c.a.i. group observation7 and
do mean that the information applies to the majorityprobably indicates that earlier smoking-related events
of CLI patients (over 60%) with less severe clinicalmight have resulted in a selection of subjects less
conditions (i.e., those not requiring major amputationsusceptible to smoking-related risk. The severity of
and those without co-morbidities implying a poorthe ischaemia apparently has a major impact on
short-term prognosis).prognosis. The significant increase in mortality, am-
In conclusion, this large clinical cohort providesputation rate and persistence of CLI with decreasing
a reliable source of prognostic and therapeuticASP clearly supports the prognostic value of peri-
information that might be used in future consensuspheral pressure measurement. However, the finding
efforts and for guidelines. It might likewise bethat only undetectable levels are predictive of mor-
useful for assessing the long-term value of varioustality and negative peripheral outcomes suggests
interventions in subgroups identified mainly on thethat the diagnostic and prognostic cut-off values so
basis of their cardiovascular risk factors, the stagefar proposed2,8–11 should be reconsidered.15 The stage
of the peripheral disease, and the suitability forof the disease still seems a more reliable predictor
invasive procedures.of poor peripheral outcome, in terms of both am-
putation and persistence of CLI. This helps answer
a question addressed in the Consensus Document2
on whether patients with both ulcer and pain have
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